Disorders of glucose metabolism are associated with increased risk for cardiovascular disease (CVD) complications, including coronary, peripheral and cerebral arterial disease, that account for the majority of morbidity and mortality among patients with diabetes mellitus (DM). These associations between glucose and CVD risk extend continuously well below the glycaemic thresholds established for the diagnosis of diabetes, including significantly increased risk associated with impaired fasting glucose, impaired glucose tolerance, and even high normal glucose concentrations. While these epidemiological observations have established a clear association between cardiovascular disease and dysglycaemia and suggest a direct causal link, the mechanisms by which hyperglycaemia may contribute to the development, progression and instability of atherosclerosis remain unclear. A number of recent advances in the realm of vascular biology have identified several novel, plausible pathways that might link hyperglycaemia with atherosclerosis, individually or in aggregate. Key among them are the interaction between advanced glycation end-products (AGEs) and the receptor for AGEs (RAGE), which exists as a trans-membrane signalling receptor and as a circulating form, soluble RAGE (sRAGE).
The purpose of this review is to provide an overview of the present understanding of RAGE and sRAGE, their plausible role linking perturbed glucose metabolism with the development, progression and instability of atherosclerosis, and the potential therapeutic implications of modulation of this biological system.
1. Zimmet P, Shaw J, Alberti KG.Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med2003;20:693–702.
2.
2. Unwin N, Shaw J, Zimmet P, Alberti KG.Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med2002;19:708–23.
3.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (ATP III). JAMA2001;285:2486–97.
4.
4. Alberti KG, Zimmet P, Shaw J.Metabolic syndrome – a new world-wide definition. A Consensus Statement from the IDF. Diabet Med2006;23:469–80.
5.
5. Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG.Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care2000;23:1242–8.
6.
6. Meigs JB, Williams K, Sullivan LM.Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care2004;27:1417–26.
7.
7. Orchard TJ, Temprosa M, Goldberg R et al.The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med2005;142:611–19.
8.
8. Hanson RL, Imperatore G, Bennett PH, Knowler WC.Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes2002;51:3120–7.
9.
9. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA.Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol2002;156:1070–7.
10.
10. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM.The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care2003;26:3153–9.
11.
11. Grundy SM, Cleeman JI, Daniels SR et al.Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation2005;112:2735–52.
12.
12. Puls WKeup U, Krause HP, Thomas G, Hoffmeister F.Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften1977;65:536–7.
13.
13. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M.STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet2002;359:2072–7.
14.
14. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M.STOP-NIDDM Trail Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA2003;290:486–94.
15.
15. Alberti KG, Zimmet PZ.Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med1998;15:539–53.
16.
16. Ilanne-Parikka P, Eriksson JG, Lindström J et al.Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention study. Diabetes Care2008;31:805–07.
17.
17. Alexander CM, Landsman PB, Teutsch SM, Haffner SM.NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes2003;25:1210–14.
18.
18. Hanefeld M, Koehler C, Gallo S, Benke I, Ott P.Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol2007;26:6–13.
19.
19. Gimeno Orna JA, Lou Arnal LM, Molinero Herguedas E, Boned Julian B, Portilla Cordoba DP Metabolic syndrome as a cardiovascular risk factor in patients with type 2 diabetes. Rev Esp Cardiol2004;57:507–13.
20.
20. Sattar N, Gaw A, Scherbakova O et al.Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation2003;108:414–19.
21.
21. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr.Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med2007;167:1068–74.
22.
22. Lorenzo C, Williams K, Hunt KJ, Haffner SM.The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care2007;30:8–13.
23.
23. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM.Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study. Circulation2000;104:42–7.
24.
24. Chen J, Wildman RP, Hamm LL, Muntner P, Reynolds K, Whelton PK, He J; 3rd National Health and Nutrition Examination Survey. Association between inflammation and insulin resistance in U.S. non-diabetic adults: results from the 3rd National Health and Nutrition Examination Survey. Diabetes Care2004;27:2960–8.
25.
25. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA.High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes2002;51:455–61.
26.
26. Knowler WC, Barrett-Connor E, Fowler SE et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002;346:393–403.
27.
27. Tuomilehto J, Lindstrom J, Eriksson JG et al.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001;344:1343–50.
28.
28. Hanefeld M, Cagaty M, Petrowitsch T, Neuser D, Petzinna D, Rupp M.Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Euro Heart J2004;25:10–16.
29.
29. Buchanan TA.How can we prevent type 2 diabetes?. Diabetes2007;56:1502–07.
30.
30. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C.Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev2005;18:CD003639.
31.
1. Gu K, Cowie CC, Harris MI.Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care1998;21:1138–45.
32.
2. UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837–53.
33.
3. The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993;329:977–86.
34.
4. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med2000;342:381–9.
35.
5. Nathan DM, Cleary PA, Backlund JY et al.Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med2005;353:2643–53.
36.
6. Goldner MG, Knatterud GL, Prout TE.Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA1971;218:1400–10.
37.
7. UK Prospective Diabetes Study (UKPDS) Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854–65.
38.
8. Dormandy JA, Charbonnel B, Eckland DJ et al.Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet2005;366:1279–89.
39.
9. Nissen SE, Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med2007;356:2457–71.
40.
10. Abraira C, Colwell J, Nuttall F et al.Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med1997;157:181–8.
41.
11. Stancoven A, McGuire DK.Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond. Am J Cardiol2007;99:S12–S17.
42.
12. Gerstein HC, Miller ME, Byington RP et al.Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008;358:2545–59.
43.
13. Patel A, MacMahon S, Chalmers J et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008;358:2560–72.
44.
14. Boyle PJ.Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med2007;120:S12–S17.
45.
15. Brownlee M, Cerami A, Vlassara H.Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med1988;318:1315–21.
46.
16. Baynes JW.Role of oxidative stress in development of complications in diabetes. Diabetes1991;40:405–12.
47.
17. Brownlee M.Advanced protein glycosylation in diabetes and aging. Annu Rev Med1995;46:223–34.
48.
18. Brownlee M, Vlassara H, Cerami A.Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes1985;34:938–41.
49.
19. Corman B, Duriez M, Poitevin P et al.Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc Natl Acad Sci U S A1998;95:1301–06.
50.
20. Kass DA, Shapiro EP, Kawaguchi M et al.Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation2001;104:1464–70.
51.
21. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D.Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb1994;14:1521–8.
52.
22. Ruef J, Peter K, Nordt TK, Runge MS, Kubler W, Bode C.Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost1999;82(suppl 1):32–7.
53.
23. Wong RK, Pettit AI, Quinn PA, Jennings SC, Davies JE, Ng LL.Advanced glycation end products stimulate an enhanced neutrophil respiratory burst mediated through the activation of cytosolic phospholipase A2 and generation of arachidonic acid. Circulation2003;108:1858–64.
54.
24. Zhang L, Zalewski A, Liu Y et al.Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation2003;108:472–8.
55.
25. Kislinger T, Fu C, Huber B et al.N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem1999;274:31740–9.
56.
26. Dyer DG, Dunn JA, Thorpe SR et al.Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest1993;91:2463–9.
57.
27. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW.N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry1995;34:10872–8.
58.
28. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR.The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem1996;271:9982–6.
59.
29. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF.The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care1998;21:1997–2002.
60.
30. Kume S, Takeya M, Mori T et al.Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol1995;147:654–67.
61.
31. Horie K, Miyata T, Maeda K et al.Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest1997;100:2995–3004.
62.
32. Nakamura Y, Horii Y, Nishino T et al.Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol1993;143:1649–56.
63.
33. Kilhovd BK, Juutilainen A, Lehto S et al.High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol2005;25:815–20.
64.
34. Kanauchi M, Tsujimoto N, Hashimoto T.Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care2001;24:1620–3.
65.
35. Schmidt AM, Vianna M, Gerlach M et al.Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem1992;267:14987–97.
66.
36. Schmidt AM, Hasu M, Popov D et al.Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A1994;91:8807–11.
67.
37. Basta G, Lazzerini G, Massaro M et al.Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation2002;105:816–22.
68.
38. Cipollone F, Iezzi A, Fazia M et al.The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation2003;108:1070–7.
69.
39. Hofmann MA, Drury S, Fu C et al.RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell1999;97:889–901.
70.
40. Bucciarelli LG, Wendt T, Qu W et al.RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation2002;106:2827–35.
71.
41. Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB.S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes2003;52:2381–8.
72.
42. Neeper M, Schmidt AM, Brett J et al.Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem1992;267:14998–5004.
73.
43. Brett J, Schmidt AM, Yan SD et al.Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol1993;143:1699–712.
74.
44. Bierhaus A, Humpert PM, Morcos M et al.Understanding RAGE, the receptor for advanced glycation end products. J Mol Med2005;83:876–86.
75.
45. Kislinger T, Tanji N, Wendt T et al.Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol2001;21:905–10.
76.
46. Harja E, Bu DX, Hudson BI et al.Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest2008;118:183–94.
77.
47. Soro-Paavonen A, Watson AM, Li J et al.Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes2008;57:2461–9.
78.
48. Abizaid A, Kornowski R, Mintz GS et al.The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol1998;32:584–9.
79.
49. The BARI Investigators: The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol2007;49:1600–06.
80.
50. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM.Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation2001;1041:815–19.
81.
51. Kornowski R, Mintz GS, Kent KM et al.Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation1997;95:1366–9.
82.
52. Zhou Z, Wang K, Penn MS et al.Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation2003;107:2238–43.
83.
53. Sakaguchi T, Yan SF, Yan SD et al.Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest2003;111:959–72.
84.
54. Bucciarelli LG, Kaneko M, Ananthakrishnan R et al.Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation2006;113:1226–34.
85.
55. Aleshin A, Ananthakrishnan R, Li Q et al.RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol2008;294:H1823–H1832.
86.
56. Andrassy M, Volz HC, Igwe JC et al.High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation2008;117:3216–26.
87.
57. Tsoporis JN, Marks A, Haddad A, Dawood F, Liu PP, Parker TG.S100B expression modulates left ventricular remodeling after myocardial infarction in mice. Circulation2005;111:598–606.
88.
58. Wang K, Zhou Z, Zhang M et al.Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J Pharmacol Exp Ther2006;317:37–43.
89.
59. Marx N, Walcher D, Ivanova N et al.Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes2004;53:2662–8.
90.
60. Cuccurullo C, Iezzi A, Fazia ML et al.Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol2006;26:2716–23.
91.
61. Yonekura H, Yamamoto Y, Sakurai S et al.Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J2003;370:1097–109.
92.
62. Raucci A, Cugusi S, Antonelli A et al.A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J2008;22:3716–27.
93.
63. Malherbe P, Richards JG, Gaillard H et al.cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res1999;71:159–70.
94.
64. Park L, Raman KG, Lee KJ et al.Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end-products. Nat Med1998;4:1025–31.
95.
65. Wendt T, Harja E, Bucciarelli L et al.RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis2006;185:70–7.
96.
66. Falcone C, Emanuele E, D'Angelo A et al.Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol2005;25:1032–7.
97.
67. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y.Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1C in type 2 diabetic patients. Diabetes Care2006;29:469.
98.
68. Koyama H, Shoji T, Yokoyama H et al.Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol2005;25:2587–93.
99.
69. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y.Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis2007;190:22–3.
100.
70. Koyama H, Shoji T, Fukumoto S et al.Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol2007;27:147–53.
101.
71. Forbes JM, Thorpe SR, Thallas-Bonke V et al.Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol2005;16:2363–72.
